XXXX antipsychotic treatment of adolescent @entity35 causes long term changes in glutamate and @entity1246 levels in the nucleus accumbens.

@entity1 @entity1246 @entity146 @entity935 @entity409 @entity854 @entity161 @entity750 @entity367 @entity35 @entity1037 @entity734
@entity734 ( @entity734 ) are widely used in @entity1 and adolescents to treat a variety of @entity146 . However, little is known about the long-term effects of AAPD treatment before the brain is fully developed. Indeed, we and others have previously reported that treatment of adolescent @entity35 with @entity1037 (OLA; a widely prescribed AAPD) on postnatal days 28-49, under dosing conditions that approximate those employed therapeutically in @entity1 , causes long-term behavioral and neurobiological perturbations. We have begun to study the mechanisms of these effects. @entity935 (DA) and @entity750 (5HT) regulate many neurodevelopmental processes. Currently approved @entity734 exert their therapeutic effects principally through their DAergic activities, although in @entity161 ( @entity161 ) and some other diseases for which @entity734 are prescribed, @entity409 is accompanied by @entity854 (GLUergic) and y-aminobutyric acidergic (GABAergic) transmission. Here, we use proton magnetic resonance spectroscopy ((1)H MRS) to investigate the effects of adolescent OLA administration on @entity1246 and @entity367 levels. We found that the treatment caused long-term reductions in the levels of both @entity367 and @entity1246 in the nucleus accumbens (NAc) of adult @entity35 treated with OLA during adolescence. The NAc is a key node in the brain's "reward" system, whose function is also disrupted in @entity161 . Further research into potential, OLA-induced changes in the levels of @entity367 and @entity1246 in the NAc and other brain areas, and the dynamics and mechanisms of those changes, are an essential step for devising new adjunct therapies for existing @entity734 and for designing new drugs that increase therapeutic effects and reduce long-term abnormalities when administered to pediatric @entity1 .
